GlassScriptPhysician profile
Katrina Cinca
NPI 1558354530
$728.44
in general payments reported to CMS, 2019-2025
10 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $105 · 2023: $114 · 2024: $168 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $285.35 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $104.22 | 2021-2025 | |
| Pfizer INC. | $98.63 | 2023-2025 | |
| Tris Pharma INC | $92.37 | 2021 | |
| Seqirus USA INC | $45.14 | 2024-2025 | Flucelvax |
| Verrica Pharmaceuticals INC. | $38.13 | 2024 | Ycanth |
| Adlon Therapeutics L.P. | $19.36 | 2021 | |
| Alk-Abello, INC | $15.52 | 2025 | Ragwitek, Odactra, Grastek |
| Cipher Pharmaceuticals US LLC | $15.46 | 2025 | Spinosad, Natroba |
| Astrazeneca Pharmaceuticals LP | $14.26 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Cinca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.